Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Seval Akpinar"'
Autor:
Seval AKPINAR, Burhan TURGUT
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 10, Iss 2, Pp 147-154 (2022)
Aim:Undetectable measurable residual disease (uMRD) after chemoimmunotherapy (CI) is associated longer progression-free survival (PFS) and overall survival. However, it remains to be demonstrated whether uMRD translates into survival benefit in patie
Externí odkaz:
https://doaj.org/article/5f4fe9e32506408cb555d15b6e6c7651
Autor:
Seval AKPINAR
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 8, Iss 3, Pp 564-569 (2020)
novel coronavirus of zoonotic origin named “severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)” emerged at the end of 2019, in Wuhan province of China. The infection called COVID-19 was declared by World Health Organization a global pan
Externí odkaz:
https://doaj.org/article/62895794e5bb4c0eb2f4e10452f79432
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 8, Iss 2, Pp 258-263 (2020)
Aim:The WW domain-containing oxidoreductase (WWOX) gene is located on chromosome 16q23.3-q24.1 and contains the common chromosomal fragile site, FRA16D. The WWOX gene encodes a Wwox tumor suppressor protein with a molecular weight of 46 kDa. Loss of
Externí odkaz:
https://doaj.org/article/5ca9e3a76c2244828d3754f1c99c3730
Autor:
Burcu Altindağ Avci, Mustafa Doğan, Bahadir Batar, İlker Yildirim, Elif Serdal, Sümbül Gezer, Çağatay L. Onar, Seval Akpinar, Burhan Turgut
Publikováno v:
Blood Coagulation & Fibrinolysis. 34:14-19
We investigated the frequency of factor 5 Leiden (FVL) and prothrombin gene (PTG) mutations in patients with severe coronavirus disease 2019 (COVID-19). Our primary aim is to reveal whether these mutations are associated with severity of disease and
Autor:
Tahir Darcın, Istemi Serın, Mehmet Can Ugur, Omer Ekinci, İpek Yönal Hindilerden, Seval Akpınar, Tuba Hacıbekiroglu, Sinan Demircioğlu, Emine Gulturk, Murat Albayrak, İsmet Aydoğdu, Mehmet Sinan Dal, Mehmet Hilmi Doğu, Sinem Namdaroğlu, Ali Dogan, Meliha Nalçacı, Burhan Turgut, Semih Başcı, Fevzi Altuntaş
Publikováno v:
Hitit Medical Journal, Vol 6, Iss 2, Pp 186-192 (2024)
Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patien
Externí odkaz:
https://doaj.org/article/9ca01e30518240fc9f0619b73350c36a
Autor:
Muhammed Enes KARDAN, Enes ARDIÇ, Seval AKPINAR, Birol ŞAFAK, Mustafa DOĞAN, Hadi SASANI, Nuri KİRAZ, Burhan TURGUT, İlknur ERDEM
Publikováno v:
Turkiye Klinikleri Journal of Internal Medicine. 6:128-132
Publikováno v:
International urology and nephrology. 54(11)
Renal involvement is present in approximately 50% of multiple myeloma (MM) cases and is associated with a poor prognosis. Procollagen C-Proteinase Enhancer 1 (PCPE-1) is an extracellular matrix glycoprotein that has been shown to increase collagen pr
Publikováno v:
Biomolecules & Biomedicine (2024)
Invasive pulmonary aspergillosis (IPA) is the most frequent invasive fungal disease occurring in patients with hematological malignancies. Serum galactomannan (GM) antigen monitoring is thought to be helpful in the diagnosis of IPA. The aim of this s
Externí odkaz:
https://doaj.org/article/1e9c18ffa7f1419c96ddae26d257b12e
Autor:
Leylagül Kaynar, Filiz Vural, Ramazan Esen, Seval Akpinar, Ismet Aydogdu, Mehmet Ali Erkurt, Hakan Goker, Fatih Demirkan, Emre Tekgündüz, Fusun Gediz, Engin Kelkitli, Orhan Ayyildiz, Mehmet Yilmaz, Serdal Korkmaz, Volkan Karakuş
Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50483605db4de6cdb6fec29f9618ea71
https://hdl.handle.net/11454/79606
https://hdl.handle.net/11454/79606
Autor:
Sehmus Ertop, Alperen Kizikli, Rahsan Yildirim, Huseyin Derya Dincyurek, Nilgun Sayinalp, Sinan Demircioğlu, Güray Saydam, Ismet Aydogdu, Abdulkadir Basturk, Erdal Kurtoğlu, Ahmet Seyhanli, Olga Meltem Akay, Hatice Terzi, Burak Deveci, Omer Ozcan, Eren Arslan Davulcu, Güven Çetin, Ali Ünal, Emel Gürkan, Vahap Okan, Elif Gülsüm Ümit, Aydan Akdeniz, Burhan Turgut, Vildan Özkocamaz, Anil Tombak, Derya Selim Batur, Mehmet Sönmez, Ilhami Berber, Burhan Ferhanoglu, Birsen Sahip, Mehmet Ali Ucar, Ahmet Kursad Gunes, Mehmet Yilmaz, Mehmet Ali Özcan, Mehmet Hilmi Dogu, Gül İlhan, Gülsüm Özet, Seval Akpinar, Funda Pepedil Tanrikulu, Demet Çekdemir, Emin Kaya, Özgür Mehtap, Mufide Okay, Irfan Yavasoglu, Salih Sertac Durusoy
Publikováno v:
Turkish Journal of Hematology
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard devia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5976c7adba53564e1d4f94514645acfd
https://hdl.handle.net/20.500.11776/8832
https://hdl.handle.net/20.500.11776/8832